Table 1:
Characteristics of patients who underwent cervical cancer screening within 2 years after stem cell transplant (SCT)
| Characteristic | Allogeneic SCT (N=436) | Autologous SCT (N=1048) | ||||
|---|---|---|---|---|---|---|
| Total (col %) | Received screening | Total (col %) | Received screening | |||
| N (row %) | p | N (row %) | p | |||
| Total | 436 | 214 (49.1) | 1048 | 446 (42.6) | ||
| Cancer type | ||||||
| Leukemia | 335 (80.0) | 176 (52.5) | 0.05 | 50 (4.8) | 27 (54.0) | <0.01 |
| Lymphoma | 65 (14.9) | 25 (38.5) | 275 (26.2) | 120 (43.6) | ||
| Myeloma | 16 (3.7) | 7 (43.8) | 592 (56.5) | 229 (38.7) | ||
| Other | 20 (4.6) | 6 (30.0) | 131 (12.5) | 70 (53.4) | ||
| Year of SCT | ||||||
| 1998–2001 | 26 (6.0) | 15 (57.7) | 0.83 | 56 (5.3) | 26 (46.4) | 0.19 |
| 2002–2005 | 44 (10.1) | 22 (50.0) | 124 (11.8) | 63 (50.8) | ||
| 2006–2009 | 107 (24.5) | 51 (47.7) | 272 (26.0) | 115 (42.3) | ||
| 2010–2013 | 259 (59.4) | 126 (48.6) | 596 (56.9) | 242 (40.6) | ||
| Age group, yr | ||||||
| <30 | 40 (9.2) | 16 (40.0) | <0.01 | 51 (4.9) | 31 (60.8) | <0.01 |
| 30–40 | 61 (14.0) | 35 (57.4) | 66 (6.3) | 42 (63.6) | ||
| 41–50 | 109 (25.0) | 66 (60.6) | 197 (18.8) | 112 (56.9) | ||
| 51–60 | 154 (35.3) | 74 (48.1) | 431 (41.1) | 190 (44.1) | ||
| 61–65 | 54 (12.4) | 21 (38.9) | 173 (16.5) | 58 (33.5) | ||
| ≥66 | 18 (4.1) | 2 (11.1) | 130 (12.4) | 13 (10.0) | ||
| Region | ||||||
| Northeast | 109 (25.0) | 50 (45.9) | 0.27 | 279 (26.6) | 111 (39.8) | 0.79 |
| North Central | 95 (21.8) | 47 (49.5) | 173 (16.5) | 73 (42.2) | ||
| South | 139 (31.9) | 76 (54.7) | 356 (34.0) | 154 (43.3) | ||
| West | 84 (19.3) | 35 (41.7) | 209 (19.9) | 93 (44.5) | ||
| Unknown | 9 (2.1) | 6 (66.7) | 31 (3.0) | 15 (48.4) | ||
| Insurance type | ||||||
| PPO | 259 (59.4) | 122 (47.1) | 0.59 | 531 (50.7) | 237 (44.6) | 0.15 |
| HMO | 55 (12.6) | 28 (50.9) | 163 (15.6) | 73 (44.8) | ||
| Other | 122 (28.0) | 64 (52.5) | 354 (33.8) | 136 (38.4) | ||
| Comorbiditya | ||||||
| None | 283 (64.9) | 140 (49.5) | 0.83 | 704 (67.2) | 322 (45.7) | <0.01 |
| Yes | 153 (35.1) | 74 (48.4) | 344 (32.8) | 124 (36.0) | ||
| GVHD | ||||||
| No | 224 (51.4) | 124 (55.4) | <0.01 | -- | -- | |
| Yes | 212 (48.6) | 90 (42.5) | -- | -- | ||
GVHD: graft vs. host disease; HMO, health maintenance organization; PPO, preferred provider organization.
a
Comorbidity based on Deyo comorbidity index [reference 18: Deyo RA, Cherkin DC, Ciol MA. Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol. 1992 Jun;45(6):613–619].